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Abstract
Background: Macrophages have been implicated in the pathogenesis of COPD. M1 and M2 macrophages
constitute subpopulations displaying pro- and anti-inflammatory properties. We hypothesized that smoking
cessation affects macrophage heterogeneity in the lung of patients with COPD. Our aim was to study macrophage
heterogeneity using the M2-marker CD163 and selected pro- and anti-inflammatory mediators in bronchoalveolar
lavage (BAL) fluid and induced sputum from current smokers and ex-smokers with COPD.
Methods: 114 COPD patients (72 current smokers; 42 ex-smokers, median smoking cessation 3.5 years) were
studied cross-sectionally and underwent sputum induction (M/F 99/15, age 62 ± 8 [mean ± SD] years, 42 (31-55)
[median (range)] packyears, post-bronchodilator FEV1 63 ± 9% predicted, no steroids past 6 months). BAL was
collected from 71 patients. CD163+ macrophages were quantified in BAL and sputum cytospins. Pro- and anti-
inflammatory mediators were measured in BAL and sputum supernatants.
Results: Ex-smokers with COPD had a higher percentage, but lower number of CD163+ macrophages in BAL than
current smokers (83.5% and 68.0%, p = 0.04; 5.6 and 20.1 ×104/ml, p = 0.001 respectively). The percentage CD163+
M2 macrophages was higher in BAL compared to sputum (74.0% and 30.3%, p < 0.001). BAL M-CSF levels were
higher in smokers than ex-smokers (571 pg/ml and 150 pg/ml, p = 0.001) and correlated with the number of
CD163+ BAL macrophages (Rs = 0.38, p = 0.003). No significant differences were found between smokers and ex-
smokers in the levels of pro-inflammatory (IL-6 and IL-8), and anti-inflammatory (elafin, and Secretory Leukocyte
Protease Inhibitor [SLPI]) mediators in BAL and sputum.
Conclusions: Our data suggest that smoking cessation partially changes the macrophage polarization in vivo in the
periphery of the lung towards an anti-inflammatory phenotype, which is not accompanied by a decrease in
inflammatory parameters.
Background
Chronic obstructive pulmonary disease (COPD) is char-
acterized by progressive lung function decline and an
abnormal inflammatory response in the airways, mainly
caused by cigarette smoke [1]. The inflammation
response in the small airway in COPD is characterized
by the accumulation of macrophages, neutrophils, CD8
+-lymphocytes and B-cells and is associated with the
severity of COPD [2,3]. Smoking cessation is an effective
treatment to reduce lung function decline [1]. Neverthe-
less, airway inflammation in bronchial biopsies, sputum
and bronchoalveolar lavage (BAL) of COPD patients
(predominantly) persists one year after smoking cessa-
tion [4-6]. We previously showed that the number of
macrophages and neutrophils in bronchial biopsies are
comparable in current and ex-smokers with COPD [7].
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However, the effects of smoking on macrophage pheno-
types in COPD are incompletely understood.
Macrophages play an important role in innate and
adaptive immunity and form a heterogeneous popula-
tion [8,9]. Macrophages display polarized phenotypes by
which they can be divided into subpopulations. Pro-
inflammatory, or classically activated macrophages (M1)
display pro-inflammatory and cytotoxic properties and
can eradicate intracellular pathogens. In contrast, anti-
inflammatory or alternatively activated macrophages
(M2) display anti-inflammatory properties and are impli-
cated in repair [8,10]. Granulocyte-macrophage colony
stimulating factor (GM-CSF) can generate M1 in vitro
from human peripheral blood monocytes, and macro-
phage colony stimulating factor (M-CSF) can generate
M2 [11]. M1 secrete pro-inflammatory cytokines, like
IL-(Interleukin)-12 and tumor necrosis factor (TNF)-a,
have good antigen presenting capacity and promote Th1
immunity. In contrast, M2 secrete anti-inflammatory
mediators, such as IL-10, show poor antigen presenting
capacity and promote development of T-regulatory cells
[11-13]. Alveolar macrophages show anti-inflammatory
M2-characteristics [14-16], which can be distinguished
from pro-inflammatory macrophages using M2 markers
such as the scavenger receptor CD163 [17,18]. Com-
pared to M1 cells, M2 macrophages are highly phagocy-
tic. The phagocytic capacity of alveolar macrophages is
decreased in smoking COPD patients and improves with
smoking cessation [19]. This suggests a phenotypic
alteration and a role of macrophage heterogeneity in
COPD, which has also been proposed in e.g. tumor pro-
gression [20], atherosclerosis [21] and renal diseases
[22].
Although inflammation persists, smoking cessation
shows positive clinical effects [1]. This suggests that
other mechanisms play a beneficial role, for instance
regulation of macrophage polarization. We hypothesize
that in moderate to severe COPD patients i) ex-smokers
have more M2 and anti-inflammatory mediators in BAL
and induced sputum compared to current smokers;
ii) M2 and anti-inflammatory mediators are relatively
higher in the peripheral airways (as sampled by BAL)
than in the central airways (as sampled by induced
sputum).
Methods
Subjects and study design
Patient characteristics and methods have been described
previously [7,23,24]. In short, we studied 114 clinically
stable moderate to severe COPD patients [GLUCOLD
study (Groningen Leiden Universities Corticosteroids in
Obstructive Lung Disease)] cross-sectionally. They were
aged 45-75 years, smoked ≥10 packyears and were cur-
rent or ex-smokers (quit ≥1 month). Patients diagnosed
with asthma, a1-antitrypsin deficiency and those who
used corticosteroids in the past six months were
excluded; they were allowed to use short-acting bronch-
odilators. Approval of the medical ethics committees of
both centers was obtained and all patients provided
written informed consent [23]. Spirometry was per-
formed according to international guidelines [25]. All
patients underwent a bronchoscopy with BAL and a
sputum induction on separate visits.
Bronchoscopy, BAL and sputum induction
Fiberoptic bronchoscopy was performed in all patients
and processed using a standardized protocol, as pre-
viously described [7,24,26,27]. The BAL procedure was
discontinued during the study due to ethical considera-
tions, since four of 71 patients experienced a serious
adverse event that was considered to be possibly related
to the BAL procedure (pleural pain, fever, pneumonia,
short-term cardiac ischemia). Sputum induction was
achieved using hypertonic sodium chloride aerosols (w/v
4.5%) for a maximal duration of three times five minutes
and processed according to the whole sample method.
BAL and sputum processing
BAL was filtered through a nylon gauze and centrifuged
for 10 minutes at 450*g at 4°C. If erythrocytes were
macroscopically present, the cell pellet was resuspended
in lysisbuffer (100 ml phosphate buffered saline (PBS)
containing 0.83 gram NH4Cl, 0.1 gram KHCO3 and
0.004 gram Ethylenediaminetetra Acetic Acid (EDTA),
pH 7.4) for 5 minutes and centrifuged (450*g, 4°C). The
cell pellet was resuspended in 0.1% glucose (w/v) in PBS
and centrifuged again under the same conditions. BAL
processing and differential cell counts were performed
analogous to the methods described for sputum proces-
sing, except that no dithiothreitol was used for homoge-
nization. The viability of the non-squamous cells in BAL
was similar in smokers and ex-smokers (82 ± 12% ver-
sus 82 ± 9%, p = 0.96).
Sputum was processed according to the whole sample
method and all samples were treated with dithiothreitol
0.1% (DTT, Sputolysin, Calbiochem) [28]. Cell free
supernatants of both BAL and sputum were stored at
-80°C.
From both BAL and sputum samples cytospins were
centrifuged on apex-coated slides [28]. A sputum sample
was considered adequate when the percentage squamous
cells was less than 80%. After drying for 1 hour, the
cytospins were wrapped in aluminum foil and stored at
-80°C pending immunocytochemical staining.
Immunocytochemical staining
Frozen cytospins of BAL and sputum were brought to
room temperature in one hour. BAL cytospins were
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fixed in acetone at -20°C for 10 minutes, dried and
endogeneous peroxidase activity was blocked by incuba-
tion in methanol and 0.3% hydrogen peroxide for 10
minutes. Sputum cytospins were fixed in 4% paraformal-
dehyde in PBS 0.9% (w/v) for 1 hour, rinsed with PBS
and endogenous peroxidase activity was blocked with
sodium azide 0.1% (w/v) and hydrogen peroxide 0.18%
(w/v) in PBS for 30 minutes. Non-specific binding was
blocked in PBS, 1% bovine serum albumin (BSA) and
5% normal human serum (NHS) for 45 minutes for the
sputum cytospins only. Mouse-anti-human CD163
(clone GHI/61, BD Pharmingen) was used as a primary
antibody to stain M2-type macrophages [17] at the dilu-
tion of 1:75 for BAL cytospins and 1:50 for sputum
cytospins, and both were incubated for one hour at
room temperature. The primary antibody was diluted in
PBS/1% BSA for BAL cytospins and in PBS/1%BSA/1%
NHS for sputum cytospins. The horseradish peroxidase
conjugated anti-mouse Envision system (DAKO,
Glostrup, Denmark) was used as a secondary antibody
and was incubated for 30 minutes, the chromogen
NovaRed (Vector, Burlingame, CA) for 7 minutes. All
washing steps were with PBS. All slides were counter-
stained with Mayer’s hematoxylin (Klinipath, Duiven,
The Netherlands) and mounted afterwards with Pertex
mounting medium (HistoLab, Gothenburg, Sweden).
We considered the possibility that DTT used to
liquefy the induced sputum samples affects detection of
CD163. To this end we generated M1 and M2 by cul-
ture of monocytes for six days in the presence of GM-
CSF and M-CSF respectively [11], and treated these
cells with DTT prior to FACS-based analysis of CD163
expression and preparation of cytospins followed by
immunocytochemical staining for CD163.
Analysis of cytospins
Two cytospins per sample were stained for differential
cell counts with May-Grünwald Giemsa (MGG). Differ-
ential cell counts were expressed as a percentage of
nucleated cells, squamous cells excluded. The median
percentage squamous cells was 7.5% (2.1-13.3%). CD163+
and CD163- macrophages were enumerated based on
morphology by two independent, experienced research-
ers at 400× magnification (figure 1). To avoid observer
bias, slides were coded without knowledge of clinical
data. The mean number of CD163+ macrophages
divided by the total counted number of macrophages
was used to calculate the percentage of CD163+
macrophages. The total number of CD163+ macro-
phages per volume was calculated by the percentage of
CD163+ macrophages multiplied by the total number
of macrophages. Repeatability between the two obser-
vers (LIK and SVW) was good, as measured by the
intraclass coefficient (ICC), with the two way random
model and absolute agreement. For BAL CD163+ and
CD163- macrophages the ICC were both 95%; for spu-
tum CD163+ and CD163- macrophages the ICC were
97% and 93% respectively.
Enzyme-linked Immunosorbent Assay (ELISA)
Commercially available kits were used to detect GM-
CSF (Bender Medsystems), M-CSF (R&D systems), IL-6,
IL-8, IL-10 (Sanquin), IL-12 (IL-12/IL-23p40, R&D sys-
tems) and elafin (HBT) in sputum and BAL superna-
tants. SLPI ELISA was developed in our laboratory at
the Leiden University Medical Center [29]. The absor-
bance was measured at 450 nm using a Microplate
reader (model 680; Bio-Rad, Hercules, CA) and Micro-
plate Manager software (version 5.2.1, Bio-Rad). The
lower limits of detection for sputum were 300 pg/ml
(SLPI), 2.5 ng/ml (elafin), 38 pg/ml (IL-6) and 400 pg/
ml (IL-8). The lower limits of detection for BAL were
150 pg/ml (M-CSF), 0.2 ng/ml (SLPI), 5.5 pg/ml (IL-6)
and 15 pg/ml (IL-8). In BAL and sputum supernatants,
IL-10, IL-12, GM-CSF levels were below the lower limit
of detection. Furthermore, elafin and M-CSF were unde-
tectable in BAL and sputum supernatants respectively.
In case more than 10% of the samples were below the
detection limits, the value of these samples was set at
the lower limit of detection (M-CSF and IL-6 in BAL).
Statistical analysis
Mean values and standard deviations (SD) or medians
with interquartile ranges (IQR) are presented. When
appropriate, variables were logarithmically transformed
before statistical analysis. Differences between smokers
and ex-smokers were explored using c2-tests, two-tailed
unpaired t-tests and Mann-Whitney tests. We used the
Spearman (Rs) correlation coefficient to analyze correla-
tions. Multiple linear regression was used to correct for
the recovery of BAL. The statistical analysis was per-
formed with SPSS 16.0 software (SPSS Inc., Chicago,
IL). Statistical significance was inferred at p < 0.05.
Results
Characteristics
In total, 114 COPD patients participated in the study, 72
current smokers and 42 ex-smokers, as presented in
table 1. All steroid-naive patients had moderate to
severe COPD (GOLD stage II-III) based on a mean (SD)
post-bronchodilator FEV1 of 63 (9)% predicted and had
a median (25th and 75th percentile) smoking history of
42 (31-55) packyears. The total group of patients and
the unselected group in which BAL was performed were
comparable. Of the BAL samples (first 71 patients), 62
were suitable for analysis. 106 out of 109 sputum induc-
tions were suitable for analysis. BAL and sputum cell
differentials and cell concentrations are presented in
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figures 2 and 3. The percentage and number of macro-
phages in BAL were significantly higher in current smo-
kers than in ex-smokers (95.8% and 74.2%, p < 0.001;
34.0 and 7.6 × 104/ml, p = 0.008 respectively). The
mean recovery of BAL was 41 (18)%; the recovery in
smokers was higher compared to ex-smokers (45 (16)%
and 35 (19)%, p = 0.039 respectively).
Smoking status and CD163+ macrophages in BAL and
induced sputum
DTT used to liquefy the induced sputum did not affect
detection of CD163 by FACS and immunocytochemical
staining (data not shown). Ex-smokers with COPD had
a significantly higher percentage of anti-inflammatory
CD163+ macrophages in BAL than current smokers
(83.5% and 68.0%, p = 0.04, respectively) (figure 4), inde-
pendent of BAL recovery. However, ex-smokers had a
lower number of anti-inflammatory macrophages in
BAL compared to current smokers (5.6 and 20.1 × 104/
ml, p = 0.001, respectively). The percentage CD163+
macrophages was higher in BAL compared to sputum
(74.0% and 30.3%, p < 0.001, respectively). Ex-smokers
had a similar percentage and number of anti-inflamma-
tory macrophages in induced sputum compared to cur-
rent smokers with COPD (25.0% and 31.1%, p = 0.89;
10.1 and 6.8 ×104/ml, p = 0.24 respectively).
Smoking status and soluble mediators in BAL and
induced sputum supernatants
BAL M-CSF levels were lower in ex-smokers than cur-
rent smokers (p = 0.001) (figure 5 and table 2). This dif-
ference was neither explained by differences in BAL
recovery between both groups, nor by the ratio of M-
CSF to anti-inflammatory macrophages. No correlation
was found between recovery and BAL M-CSF levels.
The anti-inflammatory mediator SLPI in BAL was inver-
sely correlated with recovery. The pro-inflammatory
mediators IL-6 and IL-8 in BAL were comparable
between smokers and ex-smokers and were independent
of recovery. No difference was found in induced sputum
for the pro-inflammatory IL-6, IL-8 levels and the anti-
inflammatory mediator elafin. The levels of SLPI, IL-6
and IL-8 in sputum were higher than the levels in BAL
(all p < 0.001). M-CSF was below the lower limits of
detection in induced sputum and elafin was undetect-
able in BAL.
Correlation between cells, mediators and lung function
The number of CD163+ macrophages in BAL correlated
with FEV1 post-bronchodilator (%predicted) (Rs = 0.255;
p = 0.05) and FEV1/IVC% (Rs = 0.374; p = 0.004). No
correlations were found between the number and per-
centage CD163+ macrophages in BAL and sputum and
the number of packyears or the duration of smoking
cessation. No correlations were found between the num-
ber of packyears or duration of smoking cessation and
concentrations of all soluble mediators in BAL and
induced sputum.
Figure 1 Photomicrograph of membrane-bound CD163 staining on BAL and sputum cells. A BAL cytospin is shown in the left
photograph and a sputum cytospin in the right photograph. Scale bar = 20 μm.






Males (n (%)) 59 (81.9) 40 (95.2)*
Age (years) 60.1 (7.7) 64.1 (7.2)*
Packyears 43.3 (32.4-55.6) 36.8 (27.5-53.1)
Smoking cessation (years) 3.5 (1.0-9.8)
FEV1 post-bronchodilator (L) 2.02 (0.46) 2.05 (0.46)
FEV1 post-bronchodilator (%pred) 63.3 (8.3) 62.5 (9.6)
FEV1/IVC% post-bronchodilator 49.5 (8.5) 46.0 (8.3)*
KCO (%pred) 73.3 (25.1) 80.4 (25.9)
Data are presented as mean (SD) or median (IQR) unless otherwise stated.
These patient characteristics have been previously described [7].
pred = predicted; FEV1 = forced expiratory volume in one second; IVC =
inspiratory vital capacity; KCO = carbon monoxide transfer coefficient.
* p < 0.05 compared with smokers with COPD (c2 test for sex differences, two
tailed unpaired t-tests for other data).
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BAL M-CSF correlated with the number of CD163+
macrophages in BAL (Rs = 0.379; p = 0.003). BAL SLPI
was negatively correlated with the number and percen-
tage of macrophages and positively correlated with the
number and percentage of neutrophils in BAL (all p <
0.05). BAL SLPI and the number of CD163+ macro-
phages correlated inversely (Rs = -0.353; p = 0.008).
Sputum SLPI correlated with the number and percen-
tage of CD163+ macrophages in sputum (Rs = 0.377;
p < 0.001 and Rs = 0.236; p = 0.021, respectively). Both
BAL and sputum IL-8 correlated inversely with percen-
tage macrophages, but positively with the percentage
and number of neutrophils (all p < 0.05). This relation
was not seen for IL-6. A trend was seen for a correlation
between sputum IL-8 and the percentage of CD163+
macrophages (Rs = -0.189; p = 0.061). The percentage,
but not the number, of CD163+ macrophages in BAL
showed a trend for correlation with sputum (Rs = 0.267,
p = 0.053).
Discussion
This study is the first to show that the percentage of
macrophages with anti-inflammatory, M2-type charac-
teristics (as shown by CD163 expression) is significantly
higher in BAL from ex-smokers than in current
smokers with COPD. In addition, the percentage of
anti-inflammatory macrophages was higher in BAL than
in induced sputum, indicating a predominance of this
macrophage phenotype in the periphery of the lung.
BAL M-CSF correlated with the number of CD163+
macrophages in BAL. The results together are in line
with the hypothesis that smoking cessation causes a
shift in the phenotype of luminal macrophages towards
a more anti-inflammatory phenotype, which is restricted
to the periphery of the lung. Although we did observe a
higher percentage of M2-type macrophages in BAL
from ex-smokers, this was not accompanied by a
decrease in inflammatory parameters such as neutro-
phils and pro-inflammatory mediators.
Our study shows that ex-smokers with COPD have a
higher percentage of anti-inflammatory macrophages in
BAL than current smokers. Our findings on pulmonary
macrophage polarization further extend previous obser-
vations. First, we discovered that macrophages recovered
from induced sputum have less anti-inflammatory fea-
tures than from BAL. A previous study showed that
induced sputum of COPD patients contains a majority
of pro-inflammatory macrophages, based on their
Figure 2 BAL differential cell counts expressed as percentage and cell concentrations of COPD patients. Percentage is shown in the left
panel, cell concentrations in the right panel. Open circles represent ex-smokers, closed circles represent current smokers. Horizontal bars
represent medians. P-values are corrected for recovery of BAL fluid using multiple linear regression.
Figure 3 Sputum differential cell counts expressed as percentage and cell concentrations of COPD patients. Percentage is shown in the
left panel, cell concentrations in the right panel. Open circles represent ex-smokers, closed circles represent current smokers. Horizontal bars
represent medians.
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HLA-DR expression and capacity to produce TNFa, in
contrast to control subjects [30]. However, these authors
only analyzed markers of pro-inflammatory macro-
phages and most patients used corticosteroids which
may have affected the macrophage phenotype [17].
Second, we showed that ex-smokers have more anti-
inflammatory macrophages in BAL than current smo-
kers. This is in line with a recent paper, showing that
never smokers compared to current smokers had higher
BAL levels of CCL18, a chemokine expressed by alterna-
tively activated macrophages [31]. Furthermore, previous
studies have shown that anti-inflammatory macrophages
have a higher phagocytic capacity [8,10]. Therefore our
findings are in line with another study demonstrating
that alveolar macrophages of current smokers with
COPD show reduced phagocytosis compared to ex-
smokers [19]. In addition, active smoking, but also the
presence of COPD itself, may be associated with an
impaired phagocytic capacity of alveolar macrophages
(and therefore a predominance of pro-inflammatory
macrophages) [32-34]. However, in contrast to these
and our findings, a recent study indicated that smoking
may enhance macrophage differentiation into an anti-
inflammatory phenotype, since cigarette smoking polar-
ized human alveolar macrophages of COPD patients
in vivo towards an enhanced expression of M2-related
genes and a suppression of M1 genes [35]. This study
included only 12 COPD patients with predominantly
GOLD stage I. A possible explanation for this apparent
difference with our observations is therefore that the
direction of the effect of smoking on macrophage differ-
entiation may be determined by disease severity.
Previously, several studies have evaluated the effect of
smoking on soluble mediators. We found comparable
SLPI levels in BAL between current smokers and
ex-smokers with COPD, in line with results from a
Figure 4 The percentage and number of CD163+ macrophages in BAL and induced sputum in COPD patients. The percentage (left
panel) and number of CD163+ macrophages (right panel) in BAL and induced sputum between ex-smokers (open symbols) and smokers (closed
symbols) with COPD. Horizontal bars represent medians. P-values are corrected for recovery of BAL fluid using multiple linear regression.
Figure 5 Soluble mediators measured in BAL and induced sputum supernatants of COPD patients. Ex-smokers are represented by open
symbols and smokers by closed symbols. Horizontal bars represent medians. P-values are corrected for recovery of BAL fluid using multiple
linear regression.
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study of 25 smoking, ex-smoking and never smoking
COPD patients with GOLD stage II-III [36]. We did not
find a difference in BAL IL-6 and IL-8 and sputum IL-6
between current smokers and ex-smokers with COPD,
in line with two previous studies [37,38].
We believe that our study has several strengths. We
studied a large cohort of well-characterized COPD
patients in which sputum (n = 114) and BAL (n = 71)
were collected, whereas previous studies were of smaller
size [30,31,36,39]. In addition, we studied steroid-naive
patients, excluding possible influences of inhaled corti-
costeroid therapy on CD163 expression. This is impor-
tant, since it has been shown in previous studies that
dexamethasone induces CD163 expression on mono-
cytes and macrophages in vitro [17]. The BAL and spu-
tum cytospins were counted manually by two
independent researchers simultaneously (LIK and SVW).
CD163- macrophages as well as CD163+ macrophages
were readily recognized. Repeatability between the
observers was good, as measured by the intraclass corre-
lation coefficient (data not shown).
A number of limitations needs to be taken into account
when interpreting our results. First, this was a cross-
sectional study and it cannot be ruled out that our group
of ex-smokers quit smoking because they experienced
more smoking related symptoms and they may have had
different macrophage phenotypes before quitting. In
addition, we did not confirm smoking status by labora-
tory tests which is in line with other cross-sectional stu-
dies [4,5] and therefore cannot exclude the possibility
that some ex-smokers were still smoking. Second, BAL
samples were not available from all subjects in our study
due to ethical considerations. As this was not anticipated,
it is unlikely that a selection bias for the BAL results was
introduced. Nevertheless, a significant difference in anti-
inflammatory macrophages in BAL was found between
smokers and ex-smokers. Further studies are needed to
investigate whether the observed differences in CD163
staining on macrophages are also observed when com-
paring current or ex-smokers without COPD to non-
smokers and whether CD163 expression is a specific fea-
ture of COPD. Third, we only focused on the marker
CD163 for M2 macrophages, which can result in an over-
simplification of our conclusions. Furthermore, it appears
that the M2 macrophage population is more heteroge-
neous than the M1 population [9] and M2 subpopula-
tions were not taken into account in our analysis.
Obviously, it is of interest to evaluate whether the use of
pro-inflammatory or other anti-inflammatory markers
(like arginase or iNOS) can confirm our results and
whether associated functional differences can be
detected. Currently, there is no general agreement on
well defined markers for M1 macrophages.
Fourth, we found that the percentage CD163+ cells is
higher in ex-smokers with COPD whereas the number
of CD163+ cells is higher in current smokers with
COPD. In addition, we observed a higher percentage
and number of macrophages in BAL from smokers
compared to ex-smokers, which likely results from more
active recruitment of monocytes from the circulation.
Therefore, it is not surprising that smokers have a
higher number of CD163+ cells in BAL, since they have
more macrophages in BAL. We hypothesize that percen-
tages and numbers provide different and complimentary
information: percentages better reflect the environment
during differentiation, whereas cell numbers result from
both recruitment and differentiation. Fifth, several solu-
ble mediators were below the lower limits of detection
in sputum and BAL supernatants. Finally, analysis of
cytospins using immunocytochemistry is a semi-quanti-
tative measurement and could therefore result in incor-
rect interpretations. Using e.g. FACS analysis ideally
combined with functional analysis of e.g. the phagocytic
capacity of the macrophages, could have been more
accurate to evaluate the equilibrium between pro- and
anti-inflammatory macrophages in our samples. Unfor-
tunately, fresh samples were not available at the time of
this research.
How can we explain our results? Macrophages in the
periphery of the lung in healthy individuals display
mainly anti-inflammatory characteristics that may be
involved in suppressing inflammation in this area of the
lung. Our study, as well as recent data from others
[19,40], suggest that the anti-inflammatory environment
may change into a pro-inflammatory environment as
COPD develops in smokers. This is in line with the
observation that IL-10 levels are lower and GM-CSF
and Matrix Metalloproteinase (MMP)-12 levels are
higher in sputum and BAL from COPD patients com-
pared to healthy controls [39,41,42]. Inflammatory lung
diseases, including COPD [43], are characterized by
Table 2 Soluble mediators measured in BAL and induced
sputum supernatants of smokers and ex-smokers with
COPD
Soluble mediator Ex-smokers Smokers
BAL
SLPI (ng/ml) 156 (72-386) 87 (48-154)
M-CSF (pg/ml) 150 (150-159) 571 (150-927)
IL-6 (pg/ml) 6 (6-6) 6 (6-6)
IL-8 (pg/ml) 83 (43- 193) 64 (37-122)
Sputum
SLPI (ng/ml) 5897 (4406-8628) 6643 (4321-8862)
Elafin (ng/ml) 44 (20-102) 44 (12-101)
IL-6 (pg/ml) 23 (10-36) 30 (11-58)
IL-8 (pg/ml) 3454 (1178-5212) 2571 (805-5900)
Data are presented as medians (IQR 25-75th percentile).
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increased local production of GM-CSF which may con-
tribute to development of a pro-inflammatory macro-
phage phenotype in addition to its established effect on
neutrophil survival [44]. Macrophages maintain their
plasticity even when differentiated into M1 or M2 cells
and can switch their phenotype dependent on the pre-
sence of appropriate stimuli [45,46]. In this study we
add to the field that smoking cessation may skew alveo-
lar macrophage heterogeneity towards a more anti-
inflammatory phenotype as characterized by the M2
marker CD163. Pro-inflammatory macrophages are the
predominant phenotype in the central airways, which
may be explained by high exposure to pathogens and
environmental stimuli compared to macrophages in the
peripheral airways. The higher percentage and number
of neutrophils in sputum samples are in line with this
observation. The predominance of anti-inflammatory
macrophages in the periphery of the lung may help to
keep this area, which is central to gas exchange, free
from excessive inflammation.
Our results suggest that smoking cessation can change
macrophage polarization from a pro-inflammatory
towards a CD163 expressing anti-inflammatory pheno-
type, which may decrease inflammation and enhance
repair. Our findings of a positive association between a
better lung function and more anti-inflammatory M2
macrophages are in line with this. We hypothesize that
a shift in macrophage phenotype contributes to further
clinical effects of smoking cessation. Therefore, the plas-
ticity of the macrophage phenotype and the possibility
to modulate this phenotype may be relevant to the
treatment of chronic inflammation, including COPD.
Conclusions
This study shows that previous smoking cessation may
contribute to the anti-inflammatory phenotype of
intraluminal macrophages in BAL of ex-smoking
COPD patients in vivo. Additional research is needed
to further characterize this phenotype and to demon-
strate its impact on local inflammation. Furthermore,
studies are needed to investigate whether it is
restricted to luminal macrophages or is also present in
lung tissue. Prospective studies are required to show
whether anti-inflammatory treatment contributes to
the anti-inflammatory macrophage phenotype in vivo,
and whether this contributes to treatment effects on
inflammation and clinical outcomes such as lung func-
tion decline.
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